Taper Schedule: Sertraline 100mg to Escitalopram 20mg
Use a conservative cross-taper approach over 2-4 weeks, starting escitalopram at 10mg while gradually reducing sertraline by 25-50mg every 1-2 weeks, monitoring closely for withdrawal symptoms and serotonin syndrome during the overlap period.
Recommended Cross-Taper Schedule
Week 1-2:
- Start escitalopram 10mg daily (morning or evening) 1
- Continue sertraline 100mg daily
- Monitor for serotonin syndrome symptoms (agitation, tremor, tachycardia, diaphoresis) especially in first 24-48 hours 2
Week 2-3:
- Reduce sertraline to 50mg daily
- Continue escitalopram 10mg daily
- Assess tolerability and withdrawal symptoms
Week 3-4:
- Reduce sertraline to 25mg daily (or stop if patient tolerating well)
- Continue escitalopram 10mg daily
Week 4+:
- Discontinue sertraline completely
- Increase escitalopram to 20mg daily if clinically indicated (wait at least 1 week after sertraline discontinuation) 1
Critical Safety Considerations
Serotonin syndrome risk: While combining two SSRIs carries theoretical risk, the guidelines emphasize caution rather than absolute contraindication 2. Start the second SSRI at low dose, increase slowly, and monitor intensively during the first 24-48 hours after any dosage change 2.
Sertraline withdrawal: Sertraline is specifically associated with discontinuation syndrome 2. The FDA label mandates gradual dose reduction rather than abrupt cessation 3. Withdrawal symptoms include dizziness, fatigue, myalgias, headaches, nausea, insomnia, paresthesias, anxiety, and irritability 2.
Tapering principles: The 2022 CDC opioid guideline principles (applicable to any medication with withdrawal potential) recommend tapers of 10% per month or slower for long-term users, with frequent monitoring and patient collaboration 4. For SSRIs specifically, gradual reduction over days to weeks minimizes complications 5.
Alternative Approach for High-Risk Patients
If the patient has history of severe withdrawal symptoms, longer duration on sertraline (>1 year), or high anxiety about switching:
Conservative Sequential Taper (6-8 weeks):
- Weeks 1-2: Reduce sertraline 100mg → 75mg
- Weeks 3-4: Reduce sertraline 75mg → 50mg
- Weeks 5-6: Reduce sertraline 50mg → 25mg
- Week 7: Stop sertraline completely
- Week 8: Start escitalopram 10mg after 1-week washout
- Week 11+: Increase escitalopram to 20mg if needed
This approach eliminates serotonin syndrome risk but leaves the patient without antidepressant coverage during the washout period, risking depressive relapse.
Monitoring Requirements
Weekly contact (phone or in-person) during the cross-taper phase 4. Specifically assess:
- Withdrawal symptoms (dizziness, paresthesias, "brain zaps," flu-like symptoms)
- Serotonin syndrome signs (confusion, tremor, hyperreflexia, diaphoresis, fever)
- Depressive symptom recurrence
- Suicidal ideation (particularly in patients <25 years) 1, 3
Rationale for Cross-Taper vs Sequential Taper
The cross-taper approach is preferred because:
- Maintains therapeutic coverage: Prevents depressive relapse during transition
- Shorter total duration: 3-4 weeks vs 8+ weeks
- Lower discontinuation syndrome risk: Escitalopram provides serotonergic activity while sertraline is reduced
- Acceptable safety profile: Escitalopram has the least CYP450 interactions among SSRIs, minimizing drug-drug interaction concerns 2
Common Pitfalls to Avoid
- Alternate-day dosing: Never use every-other-day dosing when tapering sertraline—this causes pronounced receptor occupancy fluctuations and severe withdrawal symptoms 6
- Too-rapid taper: Reducing by more than 50% per week increases withdrawal risk 7
- Ignoring withdrawal symptoms: If withdrawal symptoms emerge, slow the taper rate or pause temporarily 4
- Inadequate monitoring: The first 24-48 hours after starting escitalopram while on sertraline requires close observation for serotonin syndrome 2
Dose Equivalency Context
Based on randomized controlled trial data, sertraline 100mg is approximately equivalent to escitalopram 18mg 8. The target dose of escitalopram 20mg represents a slightly higher equivalent dose, which may provide adequate coverage during the transition and potentially improved efficacy if the switch is due to inadequate response.